IBI306

Pipeline

Status by Indication[3][1]

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Hypercholesterolemia2 trials

A Study of IBI306 in Participants With Hypercholesterolemia

Completed·Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT04709536·306 enrolled

Multiple Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Chinese Patients With Hypercholesterolemia

Completed·Innovent Biologics (Suzhou) Co. Ltd.·Phase 2·NCT03815812·60 enrolled

Homozygous Familial Hypercholesterolemia2 trials

Evaluate the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia

Unknown status·SShenzhen People's Hospital·Phase 2/3·NCT04948008·8 enrolled

A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia

Completed·Innovent Biologics (Suzhou) Co. Ltd.·Phase 2/3·NCT04031742·18 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of IBI306 in HeFH Patients

Completed·Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT04179669·149 enrolled

Familial Hypercholesterolemia1 trial

Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial Hypercholesterolemia

Completed·Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT04289285·804 enrolled

Single Ascending Dose1 trial

Single Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Healthy Subjects.

Completed·Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT03366688·58 enrolled

1 more indication

Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia1 trial

A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of IBI306 Monotherapy in Participants With Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia (CREDIT-5)

Active, not recruiting·Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT07473960·198 enrolled

Details

Drug Info

Related News